1. history of hypersensibility or allergy to any of the vaccine compounds. 2. history of severe anaphylactic reactions of any cause. 3. fever at the baseline visit. 4. active participation in any other clinical trial or experimental intervention within last 3 months. 5. have received any vaccine (experimental or approved) within 30 days before baseline visit, except for influenza vaccine. 6. the last anti-covid vaccination was less than 4 months ago. 7. sars-cov-2 infection occurred in less than 1 month ago. 8. pregnant or nursing women. 9. child-bearing potential and sexually active women who do not use highly effective birth control methods (oral contraceptives, intrauterine device, subcutaneous implant, transdermal patch used at least within 3 months) at the time of enrolment. fertile and sexually active men not willing to strictly use (in all relationships) barrier methods of birth control throughout study. those participants (both sexes) not sexually active can participate in the study if they are committed to avoid sexual intercourse throughout study (6 months). 10. chronic diseases that require use of immunosuppressive agents or immune response modulators (for instance: systemic corticosteroids, cyclosporine, rituximab, among others). 11. cancer under active chemotherapy treatment. 12. subjects with hiv infection history. 13. subjects with chronic renal or liver disease who have shown an infectious condition that required hospitalization or treatment with intravenous drugs within the last year prior baseline visit.

1. history of hypersensibility or allergy to any of the vaccine compounds. 2. history of severe anaphylactic reactions of any cause. 3. fever at the baseline visit. 4. active participation in any other clinical trial or experimental intervention within last 3 months. 5. have received any vaccine (experimental or approved) within 30 days before baseline visit, except for influenza vaccine. 6. the last anti-covid vaccination was less than 4 months ago. 7. sars-cov-2 infection occurred in less than 1 month ago. 8. pregnant or nursing women. 9. child-bearing potential and sexually active women who do not use highly effective birth control methods (oral contraceptives, intrauterine device, subcutaneous implant, transdermal patch used at least within 3 months) at the time of enrolment. fertile and sexually active men not willing to strictly use (in all relationships) barrier methods of birth control throughout study. those participants (both sexes) not sexually active can participate in the study if they are committed to avoid sexual intercourse throughout study (6 months). 10. chronic diseases that require use of immunosuppressive agents or immune response modulators (for instance: systemic corticosteroids, cyclosporine, rituximab, among others). 11. cancer under active chemotherapy treatment. 12. subjects with hiv infection history. 13. subjects with chronic renal or liver disease who have shown an infectious condition that required hospitalization or treatment with intravenous drugs within the last year prior baseline visit.

history of hypersensibility or allergy to any of the vaccine compounds. history of severe anaphylactic reactions of any cause. fever at the baseline visit. active participation in any other clinical trial or experimental intervention within last 3 months. have received any vaccine (experimental or approved) within 30 days before baseline visit, except for influenza vaccine. the last anti-covid vaccination was less than 4 months ago. sars-cov-2 infection occurred in less than 1 month ago. pregnant or nursing women. child-bearing potential and sexually active women who do not use highly effective birth control methods (oral contraceptives, intrauterine device, subcutaneous implant, transdermal patch used at least within 3 months) at the time of enrolment. fertile and sexually active men not willing to strictly use (in all relationships) barrier methods of birth control throughout study. those participants (both sexes) not sexually active can participate in the study if they are committed to avoid sexual intercourse throughout study (6 months). chronic diseases that require use of immunosuppressive agents or immune response modulators (for instance: systemic corticosteroids, cyclosporine, rituximab, among others). cancer under active chemotherapy treatment. subjects with hiv infection history. subjects with chronic renal or liver disease who have shown an infectious condition that required hospitalization or treatment with intravenous drugs within the last year prior baseline visit.

history of hypersensibility or allergy to any of the vaccine compounds. history of severe anaphylactic reactions of any cause. fever at the baseline visit. active participation in any other clinical trial or experimental intervention within last 3 months. have received any vaccine (experimental or approved) within 30 days before baseline visit, except for influenza vaccine. the last anti-covid vaccination was less than 4 months ago. sars-cov-2 infection occurred in less than 1 month ago. pregnant or nursing women. child-bearing potential and sexually active women who do not use highly effective birth control methods (oral contraceptives, intrauterine device, subcutaneous implant, transdermal patch used at least within 3 months) at the time of enrolment. fertile and sexually active men not willing to strictly use (in all relationships) barrier methods of birth control throughout study. those participants (both sexes) not sexually active can participate in the study if they are committed to avoid sexual intercourse throughout study (6 months). chronic diseases that require use of immunosuppressive agents or immune response modulators (for instance: systemic corticosteroids, cyclosporine, rituximab, among others). cancer under active chemotherapy treatment. subjects with hiv infection history. subjects with chronic renal or liver disease who have shown an infectious condition that required hospitalization or treatment with intravenous drugs within the last year prior baseline visit.